Nasopharyngeal Infection by Streptococcus Pyogenes Requires Superantigen-Responsive Vβ-Specific T Cells
Total Page:16
File Type:pdf, Size:1020Kb
Nasopharyngeal infection by Streptococcus pyogenes requires superantigen-responsive Vβ-specific T cells Joseph J. Zeppaa, Katherine J. Kaspera, Ivor Mohorovica, Delfina M. Mazzucaa, S. M. Mansour Haeryfara,b,c,d, and John K. McCormicka,c,d,1 aDepartment of Microbiology and Immunology, Schulich School of Medicine & Dentistry, Western University, London, ON N6A 5C1, Canada; bDepartment of Medicine, Division of Clinical Immunology & Allergy, Schulich School of Medicine & Dentistry, Western University, London, ON N6A 5A5, Canada; cCentre for Human Immunology, Western University, London, ON N6A 5C1, Canada; and dLawson Health Research Institute, London, ON N6C 2R5, Canada Edited by Philippa Marrack, Howard Hughes Medical Institute, National Jewish Health, Denver, CO, and approved July 14, 2017 (received for review January 18, 2017) The globally prominent pathogen Streptococcus pyogenes secretes context of invasive streptococcal disease is extremely dangerous, potent immunomodulatory proteins known as superantigens with a mortality rate of over 30% (10). (SAgs), which engage lateral surfaces of major histocompatibility The role of SAgs in severe human infections has been well class II molecules and T-cell receptor (TCR) β-chain variable domains established (5, 11, 12), and specific MHC-II haplotypes are known (Vβs). These interactions result in the activation of numerous Vβ- risk factors for the development of invasive streptococcal disease specific T cells, which is the defining activity of a SAg. Although (13), an outcome that has been directly linked to SAgs (14, 15). streptococcal SAgs are known virulence factors in scarlet fever However, how these exotoxins contribute to superficial disease and and toxic shock syndrome, mechanisms by how SAgs contribute colonization is less clear. Using experimental murine models estab- to the life cycle of S. pyogenes remain poorly understood. Herein, lished to mimic acute nasopharyngeal infection (16), the expression we demonstrate that passive immunization against the Vβ8-target- of HLAs and that of a specific SAg [i.e., streptococcal pyrogenic ing SAg streptococcal pyrogenic exotoxin A (SpeA), or active immu- exotoxin A (SpeA)], were absolutely required for productive in- nization with either wild-type or a nonfunctional SpeA mutant, fection (17). As the upper respiratory tract is a major niche for protects mice from nasopharyngeal infection; however, only passive S. pyogenes (18), this provided one explanation as to why this path- ogen produces SAgs. Immunization with an MHC-II binding site immunization, or vaccination with inactive SpeA, resulted in high-titer mutant of SpeA also provided initial evidence that anti-SAg anti- SpeA-specific antibodies in vivo. Mice vaccinated with wild-type β + bodies could mediate protection from nasopharyngeal infection (17). SpeA rendered V 8 T cells poorly responsive, which prevented Herein, we provide evidence that passive immunization, infection. This phenotype was reproduced with staphylococcal en- β + or vaccination with a further-attenuated SpeA toxoid, affords terotoxin B, a heterologous SAg that also targets V 8 T cells, antibody-mediated protection in a murine model of S. pyogenes and rendered mice resistant to infection. Furthermore, antibody- nasopharyngeal infection. Furthermore, our vaccination experiments mediated depletion of T cells prevented nasopharyngeal infection also uncovered an antibody-independent protection phenotype by S. pyogenes, but not by Streptococcus pneumoniae, a bacterium whereby vaccination with fully functional SAg induced Vβ-specific that does not produce SAgs. Remarkably, these observations sug- T-cell unresponsiveness. Remarkably, T cells were required for ef- gest that S. pyogenes uses SAgs to manipulate Vβ-specific T cells to ficient S. pyogenes infection. Productive infection resulted in a T-cell– establish nasopharyngeal infection. dependent proinflammatory cytokine microenvironment, which may be beneficial to S. pyogenes, although T-cell depletion did not impact superantigen | Streptococcus pyogenes | T cells | infection | nasopharynx the upper respiratory tract bacterial burden of a non-SAg secreting he globally prominent bacterial pathogen Streptococcus pyo- Significance Tgenes (also commonly referred to as the group A Strepto- coccus) exists primarily as a colonizer within the human upper Superantigen toxins were defined over 25 years ago for their respiratory tract and skin, but is also capable of causing some of ability to activate T cells in a T-cell receptor β-chain variable the most aggressive and invasive infections known. Indeed, up to domain-dependent manner. This “Vβ-specific” T-cell activation 12% of some adolescent populations may be colonized asymp- is the hallmark feature of the superantigen, and although tomatically by S. pyogenes (1); yet, this pathogen remains re- these toxins can mediate dangerous human disease such as sponsible for over 700 million superficial infections, and at least toxic shock syndrome, mechanisms that explain why bacteria 500,000 deaths, primarily due to invasive infections and acquired produce superantigens have remained enigmatic. Herein, we autoimmune manifestations in resource-poor settings (2). De- provide evidence that Streptococcus pyogenes utilizes super- β spite this enormous impact on human populations, there are antigens to target functional, V -specific T cells to promote a currently no vaccines available against this pathogen (3). state of colonization providing a mechanism that helps explain S. pyogenes encodes an impressive repertoire of virulence why bacteria produce toxins that specifically activate T cells of factors that primarily function to disrupt multiple facets of the the adaptive immune system. This work also implicates the host innate immune response (4). However, one family of toxins superantigen exotoxins as potential vaccine candidates against secreted by this organism, known as superantigens (SAgs) (5), this globally important, human-specific pathogen. + + function to specifically target and activate both CD4 and CD8 Author contributions: J.J.Z., K.J.K., S.M.M.H., and J.K.M. designed research; J.J.Z., K.J.K., T cells of the adaptive immune system (6). SAgs function by I.M., and D.M.M. performed research; J.J.Z., K.J.K., and S.M.M.H. contributed new re- bridging lateral surfaces of the MHC class II (MHC-II) molecule agents/analytic tools; J.J.Z., K.J.K., S.M.M.H., and J.K.M. analyzed data; and J.J.Z. and on antigen-presenting cells with the T-cell receptor (TCR) on J.K.M. wrote the paper. T cells, in a TCR variable β-chain (Vβ)-dependent manner. In- The authors declare no conflict of interest. deed, Vβ-specific T-cell activation is the defining feature of the This article is a PNAS Direct Submission. SAg (7) and these unconventional interactions explain how SAgs See Commentary on page 10000. can activate such a large percentage of the total T-cell pop- 1To whom correspondence should be addressed. Email: [email protected]. ulation (8). In rare cases, systemic T-cell activation by SAgs can This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10. lead to the streptococcal toxic shock syndrome (9), which in the 1073/pnas.1700858114/-/DCSupplemental. 10226–10231 | PNAS | September 19, 2017 | vol. 114 | no. 38 www.pnas.org/cgi/doi/10.1073/pnas.1700858114 Downloaded by guest on September 27, 2021 organism, Streptococcus pneumoniae. This work supports the use of have been used in vaccination studies (20, 21). Consistent with toxoid SAgs as potential vaccine candidates against S. pyogenes na- this, a model of SpeA in complex with HLA-DQ8 predicted Tyr100 SEE COMMENTARY sopharyngeal infection and indicates that SAgs specifically target and would hydrogen bond with the conserved MHC-II α-chain Lys39 manipulate Vβ-specific T-cell subsets to promote the initiation (Fig. 2A), while the SpeA side chains of Leu41 and Leu42 were of infection. predicted to extend into a pocket formed by the MHC-II α1- domain (Fig. S1). Based on this analysis, we generated a triple Results mutant containing alanine substitutions at all three positions Passive Immunization with SAg-Neutralizing Antibodies Protects Mice (SpeAL41A/L42A/Y100A), henceforth known as SpeATRI (Fig. 2B). from S. pyogenes Nasopharyngeal Infection. The human upper re- SpeATRI was attenuated at all concentrations tested for activating spiratory tract represents the major ecological niche for many B6HLA mouse splenocytes compared with wild-type SpeA (Fig. strains of S. pyogenes (18), and intranasal inoculation of mice has 2C). Next, we used SpeATRI in our vaccination regimen (Fig. 2D) been used to model this environment (16, 19). Previously, we in parallel with wild-type SpeA, or a vehicle (sham) control. In- demonstrated that mouse expression of HLA class II molecules terestingly, mice vaccinated with wild-type SpeA and SpeATRI were both protected from nasopharyngeal infection compared (referred to as B6HLA mice), and S. pyogenes MGAS8232 ex- pression of SpeA, were critical host and bacterial factors, re- with sham-vaccinated mice (Fig. 2E); however, only SpeATRI- spectively, that enhanced nasopharyngeal infection by up to four vaccinated mice generated significant anti-SpeA IgG antibody ti- F orders of magnitude (17). It was also demonstrated that vacci- ters (Fig. 2 ). Low levels of anti-SpeA IgM were only detected in the SpeA -vaccinated mice, while anti-SpeA IgA were not de- nation of these mice with a SpeA MHC-II binding mutant TRI tectable from any group